Since its introduction in the 1960s, dopamine replacement therapy with its metabolic precursor L-3,4-dihydroxyphenylanaline (L-DOPA) has remained the most effective pharmacotherapy for Parkinson's disease (PD).
a general effect of L-DOPA treatment. This article will provide a summary of the most important findings from these experimental models and their impact on the search for novel therapeutic options for LID.
Maladaptive Plasticity in L-DOPA-induced Dyskinesia

Pre-synaptic Plasticity
Generally, therapeutic doses of L-DOPA given to rodent or primate models of PD typically require a substantial dopaminergic depletion before LID can be established. Even so, some animals with extensive dopamine denervation remain non-dyskinetic after chronic L-DOPA treatment. Therefore, the extent of LID cannot be solely predicted by the degree or pattern of dopaminergic depletion. 17 Dopaminergic depletion is a significant risk factor but additional, thus far undetermined factors, must also be key to the development of LID.
Large and rapid fluctuations in extracellular levels of dopamine have been regarded as the prime trigger of the motor complications associated with L-DOPA therapy.
18 Accordingly, recent positron emission tomography studies in PD patients have demonstrated large increases in putaminal dopamine release after L-DOPA administration, which correlate positively with the severity of dyskinesia. 19, 20 In line with the clinical findings, high striatal levels of dopamine have been reported in L-DOPA-treated dyskinetic rats. [21] [22] [23] The fluctuations were originally thought to be due to the loss of dopamine neurons. However, more recently it has been suggested that a reduced expression/dysfunction of the dopamine transporter in the remaining nigrostriatal terminals 21,24 and a higher density of striatal serotonergic fibres 25 may be critical contributors to changes in dopamine levels.
As the number of dopaminergic neurons decreases, the ability of the remaining terminals to convert L-DOPA into dopamine is reduced. Eventually, serotonergic neurons become the main site of L-DOPA decarboxylation in the brain. The lack of both dopamine autoreceptors and high-affinity reuptake capacity for dopamine, however, provides a source of unregulated dopamine efflux following exogenous L-DOPA administration. The delivery of CDS moved forward significantly with the introduction of devices such as the duodenal L-DOPA pump (DuoDopa) and dopamine receptor-agonist patches. New gene therapy approaches should also assist in this endeavour, utilising viral vector-mediated delivery of coding sequences for essential enzymes in the synthesis of dopamine. 33 The enzymes involved are tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, L-amino acid decarboxylase, which converts L-DOPA into dopamine, and guanosine 5'-triphosphate cyclohydrolase 1, which synthesises Dyskinesia -Advances in Understanding the Pathophysiology and Treatment Options Dopamine D3 receptors that are co-expressed with D1 receptors on the direct pathway are increased in animal models of LID and may directly interact with them through intramembrane crosstalk.
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Nevertheless, in vivo reports are conflicting, suggesting either no effect or significant improvement on the effect of manipulating activity at the D3 receptor in LID, which may or may not be at the expense of the antiparkinsonian effect of L-DOPA.
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Dopamine D2 receptor agonists are effective at alleviating some of the symptoms of the motor disorder in early stages of the disease, partly because de novo therapies do not commonly induce significant levels of dyskinesia. 58, 59 Before concluding that D1 receptors are the LID culprits, however, it must be considered that D2 receptor agonists can produce motor sensitisation 60 and are capable of inducing dyskinesia expression if L-DOPA priming has already taken place. 
Non-dopaminergic Modulators of Dyskinesia
As mentioned above, striatal function is not only modulated by nigrostriatal dopaminergic inputs. Indeed glutamatergic, corticostriatal and acetylcholine interneurons also have modulatory influences and
post-synaptic dopamine receptors co-localise with other receptors (adenosine, glutamatergic). The activity of the striatum can also be modulated by monoamines apart from dopamine, such as noradrenaline and serotonin. It may also be possible to interfere with signalling in other nuclei of the basal ganglia circuitry, such as the globus pallidus, subthalamic nucleus and substantia nigra pars reticulata (cannabinoids and opioids). Using non-dopaminergic systems to regulate the activity of the basal ganglia is likely to be highly useful in the search for antidyskinetic agents that allow the maintenance of L-DOPA efficacy on motor function.
Glutamate
Both clinical and pre-clinical data point to the importance of the glutamate system in the pathophysiology of dyskinesia. 72 Currently, the most commonly used drug for the treatment of dyskinesia is amantadine, a weak glutamatergic antagonist. 73 Pre-clinical studies have demonstrated striatal changes in glutamate receptor expression, phosphorylation and synaptic organisation in LID.
36,74
Picconi and co-workers recently showed defective corticostriatal synaptic plasticity in dyskinetic 6-OHDA-lesioned rats. 75 It was demonstrated that the corticostriatal neurons recorded from rats with LID lost the capability to depotentiate the long-term potentiation previously induced by high-frequency stimulation. subunit, whereas the levels of NR2A were decreased. 76 The reduced expression of NR2B was discovered to be parallel to altered anchoring to the membrane-associated-guanylate kinase (MAGUK) protein family. Treatment of non-dyskinetic rats with a synthetic peptide that disrupted the binding between the NR2B subunit and the MAGUK protein resulted in the expression of abnormal involuntary movements. 76 The fast glutamatergic transmission in the striatum from the cortex is also mediated by metabotrophic glutamate receptors (mGluR).
Among the different classes of mGluR, the mGluR5 receptor has repeatedly been shown to have antidyskinetic properties. [77] [78] [79] [80] [81] Antagonising the receptor blocks the maladaptive post-synaptic changes associated with LID, such as upregulation of ΔFosB, 
85-87
Opioids
The striatal output neurons are GABAergic but also co-release the opioid peptides encephalin and dynorphin, which act at the mu, delta and kappa opioid receptors. 89 In the rodent model, infusion of the kappa receptor antagonist prevented behavioural sensitisation to apomorphine, 92 while the kappa-receptor agonist TRK-820 reduced L-DOPA-mediated dyskinesia generation and LID expression in primed animals. 93 
Adenosine
The neural activity of the basal ganglia can also be modulated by adenosine, acting on adenosine A2A receptors that are abundantly expressed in several basal ganglia nuclei. 94 The adenosine A2A
receptors located on the dendritic spines of the striato-pallidal GABA neurons form functional complexes with dopamine D2 and metabotropic glutamate 5 (mGlu5) receptors 95 and can modulate dopamine-mediated motor functions.
Antagonists of the A2A receptor have been put forward as potential targets for anti-parkinsonian drugs. 94 Evidence from the use these antagnoists as antidyskinetic agents is less convincing, as are the clinical trial data obtained thus far. Pharmacological antagonism of the A2A receptor alleviated apomorphine-induced dyskinesia in MPTP-lesioned monkeys 96 but the same pharmacological agent had no effect on LID in 6-OHDA-lesioned rats. 97 Moreover, clinical trials with the A2A receptor-antagonist istradefylline actually produced a significant worsening of LID when given in conjunction with dopaminergic treatments. 98 More recent studies suggest that the addition of an adenosine agonist may lower the dose of L-DOPA required to produce functional efficacy, which may as a consequence reduce LID.
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Noradrenaline It has long been suggested that the effects of L-DOPA in PD are mediated by both the noradrenergic and dopamine systems.
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The noradrenergic system has also been implicated in LID. 104 The α 2 -adrenoreceptor antagonists reduce LID in both the MPTP-primate model, 70, 105, 106 and in 6-OHDA-lesioned rats. 15, 107, 108 Unfortunately the antidyskinetic effect in patients with PD is somewhat disputable, with data showing both a reduction of 109 and no effect on LID. 110 Recently, Buck and co-workers showed that the attenuation of LID by the α 2 -adrenoceptor antagonist idazoxan in 6-OHDA-lesioned rats was associated with a reduction in striatal extracellular levels of dopamine, 111 thus providing a possible mechanistic insight into the antidyskinetic effect of these noradrenergic drugs. New findings from the same investigators suggest that antagonists of the α 1 -adrenoceptor could also work as potential targets for new antidyskinetic drugs.
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Cannabinoids
The precise contribution of the cannabinoid (CB) system in LID has been difficult to define, since both agonists and antagonists of the CB1-receptor seem to alleviate LID. 112 The attenuating effect on LID is well-documented in both animal models of PD [113] [114] [115] [116] and in patients, but mechanistic insights have been lacking. A recent study by
Morgese and co-workers demonstrated that treatment with a CB1-receptor agonist alleviated LID in 6-OHDA-lesioned rats. 114, 115 The improvement in symptoms was inversely correlated with extracellular glutamate levels in the denervated striatum. Clinical trials need to take all of these issues into account to fully evaluate the true potential of new agents.
Conclusion
There are new pharmacological targets and strategies under investigation, at the receptor and downstream signalling cascade levels. Furthermore, is also looking towards how non-neural mechanisms influence the microenvironment of the striatum.
There are many proposed targets for treating dyskinesia, but where treatment strategies may require invasive procedures, such as neurosurgery, or risks, such as the use of viral vectors, the clinical benefit of alleviating PD symptoms through the same procedure should be a primary consideration.
Hopefully, advances in treatment will move the field into a new era of dyskinesia management, whether that be treating the dyskinesia or finding ways to avoid its development. n 
